1. Home
  2. SDHI vs OLMA Comparison

SDHI vs OLMA Comparison

Compare SDHI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SDHI
  • OLMA
  • Stock Information
  • Founded
  • SDHI 2024
  • OLMA 2006
  • Country
  • SDHI United States
  • OLMA United States
  • Employees
  • SDHI N/A
  • OLMA N/A
  • Industry
  • SDHI Blank Checks
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SDHI Finance
  • OLMA Health Care
  • Exchange
  • SDHI Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • SDHI 352.4M
  • OLMA 378.9M
  • IPO Year
  • SDHI 2025
  • OLMA 2020
  • Fundamental
  • Price
  • SDHI $10.14
  • OLMA $5.46
  • Analyst Decision
  • SDHI
  • OLMA Strong Buy
  • Analyst Count
  • SDHI 0
  • OLMA 5
  • Target Price
  • SDHI N/A
  • OLMA $24.00
  • AVG Volume (30 Days)
  • SDHI 73.0
  • OLMA 450.7K
  • Earning Date
  • SDHI 01-01-0001
  • OLMA 08-11-2025
  • Dividend Yield
  • SDHI N/A
  • OLMA N/A
  • EPS Growth
  • SDHI N/A
  • OLMA N/A
  • EPS
  • SDHI N/A
  • OLMA N/A
  • Revenue
  • SDHI N/A
  • OLMA N/A
  • Revenue This Year
  • SDHI N/A
  • OLMA N/A
  • Revenue Next Year
  • SDHI N/A
  • OLMA N/A
  • P/E Ratio
  • SDHI N/A
  • OLMA N/A
  • Revenue Growth
  • SDHI N/A
  • OLMA N/A
  • 52 Week Low
  • SDHI $10.02
  • OLMA $2.86
  • 52 Week High
  • SDHI $11.35
  • OLMA $13.93
  • Technical
  • Relative Strength Index (RSI)
  • SDHI N/A
  • OLMA 54.42
  • Support Level
  • SDHI N/A
  • OLMA $5.54
  • Resistance Level
  • SDHI N/A
  • OLMA $5.85
  • Average True Range (ATR)
  • SDHI 0.00
  • OLMA 0.30
  • MACD
  • SDHI 0.00
  • OLMA -0.01
  • Stochastic Oscillator
  • SDHI 0.00
  • OLMA 51.79

About SDHI Siddhi Acquisition Corp Class A Common stock

Siddhi Acquisition Corp is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: